Conference Call Begins at 4:30 p.m. Eastern
Time Today
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today
reported financial results for the three and six months ended June
30, 2017, and provided an operating forecast and program updates.
Ligand management will host a conference call today beginning at
4:30 p.m. Eastern time to discuss this announcement and answer
questions.
“Halfway through 2017, the year is coming together very well. We
are enjoying robust financial performance, we have entered into
several new licensing deals that expand our portfolio, a program
that is partnered with Melinta Therapeutics received FDA approval
in June and we have received numerous positive updates from our
OmniAb-related antibody partners,” said John Higgins, Chief
Executive Officer of Ligand. “During the quarter and in recent
weeks our partners Novartis and Amgen announced important clinical,
regulatory and commercial developments with Promacta® and
Kyprolis®, respectively, and both products posted impressive
revenues for the second quarter of 2017.”
Second Quarter 2017 Financial Results
Total revenues for the second quarter of 2017 were $28.0
million, compared with $19.5 million for the same period in 2016.
Royalties were $14.2 million, compared with $9.8 million for the
same period in 2016, an increase of 46%, primarily due to higher
royalties from Promacta, Kyprolis and EVOMELA®. Material sales were
$5.6 million, compared with $3.9 million for the same period in
2016 due to the timing of Captisol® purchases for use in
clinical trials and commercial products. License fees, milestones
and other revenues were $8.2 million, compared with $5.9 million
for the same period in 2016.
Cost of goods sold was $0.9 million for the second quarter of
2017, compared with $0.7 million for the same period in 2016.
Amortization of intangibles was $2.7 million in both periods.
Research and development expense was $4.8 million, compared with
$4.9 million for the same period of 2016. General and
administrative expense was $6.5 million, compared with $7.2 million
for the same period in 2016.
Net income for the second quarter of 2017 was $6.1 million, or
$0.26 per diluted share, compared with a net loss of $6.2 million,
or $0.30 per share for the same period in 2016. Adjusted net income
for the second quarter of 2017 was $14.9 million, or $0.67 per
diluted share, compared with $7.7 million, or $0.35 per diluted
share, for the same period in 2016.
As of June 30, 2017, Ligand had cash, cash equivalents and
short-term investments of $172.6 million. Cash generated from
operations was $10.4 million for the 2017 second quarter.
Year-to-Date Financial Results
Total revenues for the six months ended June 30, 2017 were $57.3
million, compared with $49.2 million for the same period in 2016.
Royalties were $38.4 million, compared with $24.1 million for the
same period in 2016, an increase of 59%, primarily due to higher
royalties from Promacta, Kyprolis and EVOMELA. Material sales were
$6.7 million, compared with $9.2 million for the same period in
2016 due to the timing of Captisol purchases for use in clinical
trials and commercial products. License fees, milestones and other
revenues were $12.2 million, compared with $15.8 million for the
same period in 2016, due primarily to the timing of milestones and
license fees earned including the receipt of a $6.0 million
approval milestone for EVOMELA in 2016.
Cost of goods sold was $1.2 million for the six months ended
June 30, 2017, compared with $1.7 million for the same period in
2016 due to the timing and mix of Captisol sales. Amortization of
intangibles was $5.4 million, compared with $5.2 million for the
same period in 2016. Research and development expense was $13.5
million, compared with $8.9 million for the same period of 2016 due
to enrollment costs of our Phase 2 GRA trial and non-cash
stock-based compensation expense. General and administrative
expense was $13.9 million, compared with $14.3 million for the same
period in 2016.
Net income for the six months ended June 30, 2017 was $11.1
million, or $0.48 per diluted share, compared with $0.4 million, or
$0.02 per diluted share, for the same period in 2016. Adjusted net
income for the six months ended June 30, 2017 was $27.6 million, or
$1.25 per share, compared with $21.3 million, or $0.98 per diluted
share, for the same period in 2016.
2017 Financial Forecast
Ligand updates guidance for 2017 revenue to be at least $133
million, including royalties of approximately $87 million, material
sales of approximately $23 million and contract payments of at
least $23 million. During the remainder of 2017, Ligand estimates
it could potentially receive up to an additional $9 million of
contract payments. The Company will provide more information about
the timing and probability for additional contract revenue, if any,
expected to be booked in 2017 as the year continues. Ligand notes
that with revenue of $133 million, adjusted earnings per diluted
share would be approximately $2.93.
Second Quarter 2017 and Recent Business Highlights
Portfolio Program Progress
Promacta®/Revolade®
- Novartis reported second quarter 2017
net sales of Promacta/Revolade (eltrombopag) of $210 million, a $52
million or 33% increase over the same period in 2016.
- Novartis reported Revolade
(eltrombopag) was approved in Canada for the treatment of pediatric
(≥1 years to <18 years) chronic immune thrombocytopenia purpura
to increase platelet counts in patients who have had an
insufficient response to corticosteroids or immunoglobulins.
- Novartis announced the publication of a
study conducted by the National Institutes of Health demonstrating
that 58% of patients with treatment-naïve severe aplastic anemia
achieved complete response at six months when treated with
eltrombopag at the initiation of and concurrent with standard
immunosuppressive treatment. The data are published in the latest
issue of The New England Journal of Medicine.
Kyprolis® (carfilzomib), an Amgen Product
Utilizing Captisol
- On July 25, 2017, Amgen reported second
quarter 2017 net sales of Kyprolis (carfilzomib) of $211 million, a
$39 million or 23% increase over the same period in 2016. On August
2, 2017, Ono Pharmaceutical Company reported Kyprolis sales in
Japan of approximately $10.8 million for the most recent
quarter.
- On July 14, 2017, Amgen announced the
submission of a supplemental New Drug Application to the FDA and a
variation to the marketing application to the EMA to include
overall survival data from the Phase 3 head-to-head ENDEAVOR trial
in the product information for Kyprolis (carfilzomib).
- On July 12, 2017, Amgen announced
positive results from the final analysis of the Phase 3 ASPIRE
trial, showing the study met the key secondary endpoint of overall
survival, demonstrating that Kyprolis (carfilzomib), lenalidomide
and dexamethasone (KRd) reduced the risk of death by 21% over
lenalidomide and dexamethasone alone.
- On June 4, 2017, a Phase 1b study
involving daratumumab in combination with KRd in patients with
newly diagnosed multiple myeloma was highlighted in an Oral
Abstract Session at the 2017 ASCO Annual Meeting.
Additional Pipeline and Partner Developments
- Spectrum Pharmaceuticals reported
second quarter 2017 net sales of EVOMELA of $10 million.
- Melinta Therapeutics announced that the
FDA approved both IV and oral Baxdela™ (delafloxacin) for the
treatment of adults with acute bacterial skin and skin structure
infections (ABSSSI) caused by susceptible bacteria. As a result of
the approval, Ligand earned a $1.5 million milestone payment and
will earn a 2.5% royalty on Baxdela IV sales. Following approval,
Melinta Therapeutics entered into a $90 million loan and securities
financing agreement with Oberland Capital Management, LLC to fund
commercialization activities and indication expansion of
Baxdela.
- CorMatrix sold the rights to its
commercial pericardial repair and CanGaroo® Envelope extracellular
matrix (ECM) products to Aziyo Biologics. The transaction included
a $10 million payment to Ligand to buy down the royalty rate and
also provided Ligand with an additional $10 million of sales-based
milestones tied to the commercial success of the two products.
- Retrophin announced that the United
States Patent and Trademark Office and the European Patent Office
each issued patents covering sparsentan for the treatment of focal
segmental glomerulosclerosis.
- Sage Therapeutics announced that The
Lancet published results from a Phase 2, double-blind, randomized
and placebo-controlled study of brexanolone in women with severe
postpartum depression.
- Aldeyra announced the last patient had
completed dosing in their multicenter, double-blind, randomized
Phase 2b clinical trial of ADX-102 in allergic conjunctivitis.
- Aldeyra announced that it enrolled the
first patient into a Phase 2a clinical trial of topical ocular
ADX-102 for the treatment of Dry Eye Disease.
- Novartis announced that it had
exercised an option to in-license ECF843 (Lubricin) for ophthalmic
indications from Lubris Biopharma. Ligand acquired economic rights
to the Lubricin program from Selexis, SA in 2015.
- Merrimack announced that it had
enrolled the last patient in the ongoing CARRIE study, a Phase 2,
double-blind, placebo-controlled, randomized trial evaluating
MM-141 (istiratumab) in combination with standard of care in
previously untreated patients with metastatic pancreatic
cancer.
- Viking Therapeutics announced
enrollment completion in the ongoing Phase 2 clinical trial of
VK5211 in patients who recently suffered a hip fracture.
- Viking Therapeutics announced positive
topline results from a preclinical study of VK2809 in an in vivo
model of non-alcoholic steatohepatitis (NASH).
- CStone Pharmaceuticals announced that
it received Clinical Trial Application approval from the China Food
and Drug Administration to conduct clinical trials in China with
CS1001, an OmniAb-derived full-length anti-PDL1 monoclonal
antibody.
- Marinus Pharmaceuticals announced that
it had initiated a Phase 2 double-blind, placebo-controlled
clinical trial to evaluate the safety, efficacy and
pharmacokinetics of ganaxolone IV in women diagnosed with severe
postpartum depression.
- Marinus Pharmaceuticals presented Phase
1 clinical data showing the safety and tolerability of ganaxolone
IV at the 6th London-Innsbruck Colloquium on Status Epilepticus and
Acute Seizures.
- Aptevo Therapeutics announced that
aspects of its ADAPTIR™ protein therapeutic platform, including
APVO436, an OmniAb-discovered antibody, were showcased at the
Americas Antibody Congress 2017 and at the 2017 Next Generation
Protein Therapeutics Summit.
- XTL Biopharmaceuticals announced the
receipt of additional preclinical data regarding the role of hCDR1
as a potential treatment for Sj�gren's syndrome from Prof. Edna
Mozes of The Weizmann Institute of Science and the developer of
hCDR1.
- Opthea Limited announced positive
results from its Phase 1/2a clinical trial of OPT-302 for wet
age-related macular degeneration (wet AMD). Opthea is planning to
initiate a Phase 2b trial in wet AMD and a Phase 2a trial in
diabetic macular edema in the second half of 2017.
New Licensing Deals
- Ligand announced worldwide license
agreements with Surface Oncology and xCella Biosciences to use the
OmniAb platform technologies to discover fully human antibodies.
Ligand is eligible to receive annual access payments, milestone
payments and royalties on future net sales of any antibodies
discovered under these licenses.
- Ligand announced a commercial license
and supply agreement with Marinus Pharmaceuticals, granting rights
to use Captisol in the formulation of IV ganaxolone. Ligand is
eligible to receive milestone payments, royalties and revenue from
Captisol material sales related to IV ganaxolone.
- Ligand announced a commercial license
and supply agreement with Amgen granting rights to use Captisol in
the formulation of AMG 330, an anti-CD33 x anti-CD3 (BiTE®)
bispecific antibody construct. Ligand is eligible to receive
milestone payments, royalties and revenue from Captisol material
sales related to AMG 330.
- Ligand announced a commercial license
and supply agreement with Interventional AnalgesiX granting rights
to use Captisol in the formulation of an undisclosed compound.
Ligand is eligible to receive milestone payments, tiered royalties
of 5%-10% and revenue from Captisol material sales.
Internal Glucagon Receptor Antagonist (GRA) Program
- Ligand continues to expect to report
topline data from the Phase 2 clinical trial with its novel,
small-molecule GRA program (LGD-6972) for the treatment of type 2
diabetes mellitus in September 2017.
Adjusted Financial Measures
The Company reports adjusted net income and adjusted net income
per diluted share, in addition to, and not as a substitute for, or
superior to, financial measures calculated in accordance with GAAP.
The Company’s financial measures under GAAP include stock-based
compensation expense, amortization of debt-related costs,
amortization related to acquisitions, changes in contingent
liabilities, net losses of Viking Therapeutics, mark-to-market
adjustment for amounts owed to licensors, fair value adjustments to
Viking Therapeutics convertible note receivable and warrants,
unissued shares relating to the Senior Convertible Note, and others
that are listed in the itemized reconciliations between GAAP and
adjusted financial measures included in this press release.
However, other than with respect to total revenue, the Company only
provides guidance on an adjusted basis and does not provide
reconciliations of such forward-looking adjusted measures to GAAP
due to the inherent difficulty in forecasting and quantifying
certain amounts that are necessary for such reconciliation,
including adjustments that could be made for changes in contingent
liabilities, net losses of Viking Therapeutics, mark-to-market
adjustments for amounts owed to licensors, effects of any discrete
income tax items and fair value adjustments to Viking Therapeutics
convertible note receivable. Management has excluded the effects of
these items in its adjusted measures to assist investors in
analyzing and assessing the Company’s past and future core
operating performance. Additionally, adjusted earnings per diluted
share is a key component of the financial metrics utilized by the
Company’s board of directors to measure, in part, management’s
performance and determine significant elements of management’s
compensation.
Conference Call
Ligand management will host a conference call today beginning at
4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss this
announcement and answer questions. To participate via telephone,
please dial (833) 591-4752 from the U.S. or (720) 405-1612 from
outside the U.S., using the Conference ID 59163454 To participate
via live or replay webcast, a link will be available at
www.ligand.com.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory affairs and commercialization)
to ultimately generate our revenue. Ligand’s Captisol® platform
technology is a patent-protected, chemically modified cyclodextrin
with a structure designed to optimize the solubility and stability
of drugs. OmniAb® is a patent-protected transgenic animal platform
used in the discovery of fully human mono- and bispecific
therapeutic antibodies. Ligand has established multiple alliances,
licenses and other business relationships with the world's leading
pharmaceutical companies including Novartis, Amgen, Merck, Pfizer,
Celgene, Gilead, Janssen, Baxter International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
Forward-Looking Statements
This news release contains forward-looking statements by Ligand
that involve risks and uncertainties and reflect Ligand's judgment
as of the date of this release. Words such as “plans,” “believes,”
“expects,” “anticipates,” and “will,” and similar expressions, are
intended to identify forward-looking statements. These
forward-looking statements include, without limitation, statements
regarding: Ligand’s future revenue growth, including the timing,
mix and volume of Captisol orders, the timing of the initiation or
completion of clinical trials by Ligand and its partners, the
timing of regulatory filings with the FDA and other regulatory
agencies, the timing of new product launches by Ligand and its
partners and the related royalties Ligand expects to receive from
its partners, the timing of review of clinical data by the FDA,
expected value creation for shareholders and guidance regarding the
full-year 2017 financial results. Actual events or results may
differ from Ligand's expectations. For example, Ligand may not
receive expected revenue from material sales of Captisol, expected
royalties on other partnered products and research or development
milestone payments. Ligand and its partners may not be able to
timely or successfully advance any product(s) in its internal or
partnered pipeline. In addition, there can be no assurance that
Ligand will achieve its guidance for 2017 or any portion thereof or
beyond, that Ligand's 2017 revenues will be at the levels as
currently anticipated, that Ligand will be able to create future
revenues and cash flows by developing innovative therapeutics, that
results of any clinical study will be timely, favorable or
confirmed by later studies, that products under development by
Ligand or its partners will receive regulatory approval, that there
will be a market for the product(s) if successfully developed and
approved, or that Ligand's partners will not terminate any of its
agreements or development or commercialization of any of its
products. Further, Ligand may not generate expected revenues under
its existing license agreements and may experience significant
costs as the result of potential delays under its supply
agreements. Also, Ligand and its partners may experience delays in
the commencement, enrollment, completion or analysis of clinical
testing for its product candidates, or significant issues regarding
the adequacy of its clinical trial designs or the execution of its
clinical trials, which could result in increased costs and delays,
or limit Ligand's ability to obtain regulatory approval. Further,
unexpected adverse side effects or inadequate therapeutic efficacy
of Ligand's product(s) could delay or prevent regulatory approval
or commercialization. In addition, Ligand may not be able to
successfully implement its strategic growth plan and continue the
development of its proprietary programs. The failure to meet
expectations with respect to any of the foregoing matters may
reduce Ligand's stock price. Additional information concerning
these and other risk factors affecting Ligand can be found in prior
press releases available at www.ligand.com as well as in Ligand's
public periodic filings with the Securities and Exchange Commission
available at www.sec.gov. Ligand disclaims any intent or obligation
to update these forward-looking statements beyond the date of this
release, including the possibility of additional contract revenues
we may receive. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Other Disclaimers and Trademarks
The information in this press release regarding certain
third-party products and programs, including Promacta, a Novartis
product, and Kyprolis, an Amgen product, comes from information
publicly released by the owners of such products and programs.
Ligand is not responsible for, and has no role in, the development
of such products or programs.
Ligand owns or has rights to trademarks and copyrights that it
uses in connection with the operation of its business including its
corporate name, logos and websites. Other trademarks and copyrights
appearing in this press release are the property of their
respective owners. The trademarks Ligand owns include Ligand®,
Captisol® and OmniAb®. Solely for convenience, some of the
trademarks and copyrights referred to in this press release are
listed without the ®, © and TM symbols, but Ligand will assert, to
the fullest extent under applicable law, its rights to its
trademarks and copyrights.
LIGAND PHARMACEUTICALS, INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands)
Three Months Ended June 30, Six Months Ended June
30, 2017 2016 2017
2016 Revenues: Royalties $ 14,211 $ 9,754 $ 38,441 $
24,144 Material sales 5,550 3,886 6,672 9,227 License fees,
milestones and other revenues 8,234 5,881 12,151
15,798 Total revenues 27,995 19,521
57,264 49,169
Operating costs and expenses:
Cost of goods sold 903 720 1,244 1,675 Amortization of intangibles
2,706 2,681 5,420 5,206 Research and development 4,822 4,914 13,495
8,915 General and administrative 6,549 7,237 13,872
14,309 Total operating costs and expenses 14,980
15,552 34,031 30,105 Income from
operations 13,015 3,969 23,233 19,064 Other expense, net (2,642 )
(2,550 ) (5,444 ) (5,163 ) Increase in contingent liabilities (825
) (332 ) (966 ) (1,638 ) Loss from Viking (1,248 ) (11,138 ) (2,330
) (12,743 ) Total other expense, net (4,715 ) (14,020 ) (8,740 )
(19,544 ) Income (loss) before income taxes 8,300 (10,051 ) 14,493
(480 ) Income tax (expense) benefit (2,242 ) 3,881 (3,356 )
187 Income (loss) from continuing operations 6,058
(6,170 ) 11,137 (293 ) Income from discontinued operations,
net of taxes — — — 731
Net income
(loss): $ 6,058 $ (6,170 ) $ 11,137 $ 438
Basic per share amounts: Income (loss) from
continuing operations $ 0.29 $ (0.30 ) $ 0.53 $ (0.01 )
Discontinued operations — — — 0.04 Net
income (loss) $ 0.29 $ (0.30 ) $ 0.53 $ 0.02
Diluted per share amounts: Income (loss) from continuing
operations $ 0.26 $ (0.30 ) $ 0.48 $ (0.01 ) Discontinued
operations — — — 0.04 Net income (loss)
$ 0.26 $ (0.30 ) $ 0.48 $ 0.02 Weighted
average number of common shares-basic 21,013 20,832 20,975 20,765
Weighted average number of common shares-diluted 23,216 20,832
23,117 20,765
LIGAND PHARMACEUTICALS,
INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)
June 30, 2017 December 31, 2016 ASSETS
Current assets: Cash, cash equivalents and short-term investments $
172,627 $ 141,048 Accounts receivable, net 13,462 14,700 Note
receivable from Viking 3,207 3,207 Inventory 6,809 1,923 Other
current assets 1,072 2,175 Total current assets 197,177
163,053 Deferred income taxes 138,837 123,891 Goodwill and other
identifiable intangible assets 271,491 276,912 Investment in Viking
6,014 8,345 Commercial license rights 22,962 25,821 Other assets
3,543 3,563 Total assets 640,024 601,585
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:
Accounts payable and accrued liabilities $ 7,124 $ 9,131 Current
portion of contingent liabilities 86 5,088 2019 convertible senior
notes, net 218,630 212,910 Total current liabilities 225,840
227,129 Long-term portion of contingent liabilities 3,860 2,916
Other long-term liabilities 915 687 Total liabilities
230,615 230,732 Equity component of currently redeemable
convertible notes 24,293 29,563 Total Ligand
Pharmaceuticals stockholders' equity 385,116 341,290 Total
liabilities and stockholders' equity 640,024 601,585
LIGAND PHARMACEUTICALS INCORPORATED
ADJUSTED FINANCIAL MEASURES
(Unaudited, in thousands)
Three months ended June 30, Six months ended June
30, 2017 2016 2017
2016 Net income (loss) $ 6,058 $ (6,170 ) $
11,137 $ 438 Stock-based compensation expense 4,624 4,647 10,669
8,766 Non-cash interest expense(1) 2,882 2,710 5,720 5,379
Amortization related to acquisitions 5,371 2,778 8,276 5,310
Increase in contingent liabilities(2) 825 332 966 1,638 Loss from
Viking 1,248 11,138 2,330 12,743 Other(3) 169 (184 ) 84 (389 )
Income tax effect of adjusted reconciling items above (5,287 )
(7,587 ) (9,769 ) (11,864 ) Excess tax benefit from stock-based
compensation(4) (952 ) — (1,827 ) — Discontinued operations, net of
tax — — — (731 ) Adjusted net income $ 14,938
$ 7,664 $ 27,586 $ 21,290
Diluted
per-share amounts attributable to common shareholders: Net
income $ 0.26 $ (0.30 ) $ 0.48 $ 0.02 Stock-based compensation
expense 0.20 0.22 0.46 0.42 Non-cash interest expense(1) 0.12 0.13
0.25 0.26 Amortization related to acquisitions 0.23 0.13 0.36 0.26
Increase in contingent liabilities(2) 0.04 0.02 0.04 0.08 Loss from
Viking 0.05 0.53 0.10 0.61 Other(3) 0.01 (0.01 ) — (0.02 ) Income
tax effect of adjusted reconciling items above (0.23 ) (0.36 )
(0.42 ) (0.57 ) Excess tax benefit from stock-based compensation(4)
(0.04 ) — (0.08 ) — 2019 Senior Convertible Notes share count
adjustment 0.03 0.02 0.05 0.04 Discontinued operations, net of tax
— — — (0.04 ) Adjusted net income $ 0.67
$ 0.35 $ 1.25 $ 0.98
GAAP-Weighted average number of common shares-diluted 23,216 20,832
23,117 20,765 Plus: Shares excluded due to anti-dilutive effect on
GAAP net loss — 2,123 — 1,850 Less: 2019 Senior Convertible Notes
share count adjustment 1,080 1,205 1,010 977 Adjusted weighted
average number of common shares-diluted 22,136 21,750 22,107 21,638
(1) Non-cash debt related costs is calculated in accordance with
the authoritative accounting guidance for convertible debt
instruments that may be settled in cash.
(2) Changes in fair value of contingent consideration related to
CyDex and Metabasis transactions.
(3) Amounts due to Bristol-Myers Squibb relating to the
Retrophin license agreement and fair market value adjustment on
Viking note and warrants.
(4) Excess tax benefits from stock-based
compensation are recorded as a discrete item within the provision
for income taxes on the consolidated statement of income pursuant
to ASU 2016-09, which was previously recognized in additional
paid-in capital on the consolidated statement of stockholders'
equity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170807005799/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill(858)
550-7500investors@ligand.comTwitter: @Ligand_LGNDorLHABruce
Voss(310) 691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024